639468-72-7

Basic information

• Product Name: phenyl(tetrahydro-2H-pyran-4-yl)Methanone
• Synonyms: phenyl(tetrahydro-2H-pyran-4-yl)Methanone;4-benzoyloxane;oxan-4-yl(phenyl)methanone
• CAS NO: 639468-72-7
• Molecular Formula: C₁₂H₁₄O₂
• Molecular Weight: 190.23836
• EINECS: -0
• Mol File: 639468-72-7.mol
• Article Data: 10

Chemical Properties

• Melting Point: 57-58 °C
• Boiling Point: 307.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.090±0.06 g/cm3(Predicted)
• CAS DataBase Reference: phenyl(tetrahydro-2H-pyran-4-yl)Methanone(CAS DataBase Reference)
• NIST Chemistry Reference: phenyl(tetrahydro-2H-pyran-4-yl)Methanone(639468-72-7)
• EPA Substance Registry System: phenyl(tetrahydro-2H-pyran-4-yl)Methanone(639468-72-7)

Safety Data

• Hazardous Substances Data: 639468-72-7(Hazardous Substances Data)

Usage

General Description

Phenyl(tetrahydro-2H-pyran-4-yl)methanone is a chemical compound with the molecular formula C14H16O2. It is a ketone derivative with a phenyl group and a tetrahydro-2H-pyran-4-yl group attached to the carbonyl carbon. phenyl(tetrahydro-2H-pyran-4-yl)Methanone may be used in organic synthesis, medicinal chemistry, and pharmaceutical research. Its specific properties, potential applications, and biological effects are subject to further study and investigation.

Upstream product

• 98-88-4 benzoyl chloride 
• 263257-15-4 (tetrahydro-2H-pyran-4-yl)magnesium chloride 
• 110238-91-0 tetrahydropyran-4-carboxylic acid methyl ester 
• 591-51-5 phenyllithium 
• 156353-01-4 N-methoxy-N-methyltetrahydro-2H-pyran-4-carboxamide 
• 34270-90-1 2,2'-diiodoethyl ether 
• 98-83-9 isopropenylbenzene 
• 101765-10-0 tetrahydro-4-(methoxymethylene)-2H-pyran 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 40191-32-0 tetrahydro-2H-pyran-4-carbonylchloride 
• 2674-04-6 diphenyl cadmium 
• 4295-99-2 tetrahydro-2H-pyran-4-carbonitrile 
• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 
• 50675-18-8 3,4,5,6-tetrahydro-2H-pyran-4-carbaldehyde 

Downstream Products

• 1800345-36-1 (S)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol 
• 1800345-36-1 (R)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol 
• 1361052-17-6 C₁₈H₁₃F₅O₂ 

Relevant articles and documents

TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF

The present applicationpresent application relates to a compound represented by Formula (III) or a pharmaceutically acceptable salt, solvent compound, active metabolite, crystal polymorph, ester, isomer, or prodrug thereof. The application further provides a pharmaceutical composition comprising the compound represented by Formula (III) and a use thereof for preparing a bromodomain inhibitor for preventing or treating various diseases, such as inflammation and cancer, related to the bromodomain.

Stereospecific Palladium-Catalyzed Acylation of Enantioenriched Alkylcarbastannatranes: A General Alternative to Asymmetric Enolate Reactions

We report the development of a Pd-catalyzed process for the cross coupling of unactivated primary, secondary, and tertiary alkylcarbastannatrane nucleophiles with acyl electrophiles. Reactions involving optically active alkylcarbastannatranes occur with exceptional stereofidelity and with net retention of absolute configuration. Because the stereochemistry of the resulting products is entirely reagent-controlled, this process may be viewed as a general, alternative approach to the preparation of products typically accessed via asymmetric enolate methodologies. Additionally, we report a new method for the preparation of optically active alkylcarbastannatranes, which should facilitate their future use in stereospecific reactions.

Non-substrate based, small molecule inhibitors of the human isoprenylcysteine carboxyl methyltransferase

Activating mutations of human K-Ras proteins are among the most common oncogenic mutations, present in approximately 30% of all human cancers. Posttranslational modifications to K-Ras guide it to the plasma membrane and disruption of this localization inhibits the growth of Ras-driven cancers. The human isoprenylcysteine carboxyl methyltransferase (hIcmt) enzyme catalyzes the final α-carboxyl methylesterification of the C-terminal farnesyl cysteine of K-Ras, which is necessary for its proper localization. Thus, hIcmt inhibition is a regarded as a promising cancer therapy. A high quality inhibitor of hIcmt with in vivo activity would advance hIcmt research and drug development. Herein, Wwe report the results of a screen for small molecule hIcmt inhibitors in a library of molecules that were not hIcmt substrate analogs. The lead compound identified by this screen (1) was modified to remove chemical liabilities and to increase potency. The most potent resulting compound (5) inhibited hIcmt in vitro with low micromolar potency (IC50 = 1.5 ± 0.2 μM) and was kinetically characterized as a competitive inhibitor for prenylated substrates and a non-competitive inhibitor for the cofactor and methyl donor S-adenosylmethionine (SAM). These inhibitors offer important structure activity relationships for the future development of hIcmt inhibitors with in vivo activity.